Loading…
Operates in Medical Devices — Distribution. Per the activity note to the FY2022 annual report, the company sells medical devices, products and equipment, and provides service support.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 52.7% | 41.2% | 61.7% | 75.2% | 31.1% |
| EBITDA Margin | 36.8% | 15.1% | 27.1% | 31.5% | 16.0% |
| EBITDAR | 812 | 303 | 646 | 820 | 1,120 |
| EBITDAR Margin | 36.9% | 15.1% | 27.4% | 31.9% | 16.0% |
| EBIT Margin | 36.6% | 14.8% | 26.8% | 31.1% | 15.9% |
| Net Profit Margin | 35.7% | 8.9% | 32.3% | 17.9% | 13.8% |
| Operating Expense % of Sales | 16.0% | 26.1% | 34.5% | 43.7% | 15.1% |
| Returns | |||||
| Return on Assets (ROA) | 43.3% | 11.6% | 45.6% | 8.4% | 105.2% |
| Return on Equity (ROE) | 59.2% | 17.3% | 59.7% | 163.9% | 148.3% |
| ROIC [EBIT / Invested Capital] | 114.2% | 59.2% | 86.2% | N/A | 179.8% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 14.3% | 17.1% | 14.2% | 5.3% | 18.7% |
| Debt-to-Equity | 0.20x | 0.26x | 0.19x | 1.03x | 0.26x |
| Debt-to-EBITDA | 0.32x | 0.87x | 0.37x | 0.36x | 0.15x |
| Equity-to-Assets | 73.0% | 67.1% | 76.4% | 5.1% | 70.9% |
| Net Debt | -622 | -535 | -542 | -291 | -31 |
| Cash & Equivalents | 882 | 800 | 779 | 580 | 202 |
| Total Debt | 260 | 265 | 237 | 289 | 171 |
| Liquidity & working capital | |||||
| Current Ratio | 1.21x | 0.05x | 113.96x | 0.03x | 1.37x |
| Quick Ratio | 1.21x | 0.01x | 101.18x | 0.03x | 1.37x |
| Cash Ratio | 3.84x | 3.47x | 130.43x | 0.12x | 2.14x |
| Total Current Assets | 279 | 12 | 681 | 129 | 129 |
| Total Current Liabilities | 230 | 230 | 6 | 4,889 | 94 |
| Inventory | N/A | 9 | 76 | N/A | N/A |
| Trade Receivables | 626 | 506 | 777 | 332 | 440 |
| Trade Payables | 230 | 230 | 6 | 1 | 94 |
| Net Working Capital | 49 | -219 | 675 | -4,760 | 34 |
| Net Working Capital % of Revenue | 2.2% | -10.9% | 28.6% | -185.3% | 0.5% |
| Trade Working Capital | 396 | 285 | 847 | 332 | 346 |
| Trade Working Capital % of Revenue | 18.0% | 14.2% | 36.0% | 12.9% | 4.9% |
| Change in Trade Working Capital | N/A | -111 | 562 | -516 | 14 |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | 132.32x | 11.83x | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 2.8 | 30.9 | N/A | N/A |
| Receivables Turnover | 3.52x | 3.97x | 3.03x | 7.73x | 15.89x |
| Days Sales Outstanding (DSO) | 103.7 | 92.0 | 120.4 | 47.2 | 23.0 |
| Payables Turnover | 4.53x | 5.13x | 151.15x | 919.93x | 51.09x |
| Days Payable Outstanding (DPO) | 80.6 | 71.1 | 2.4 | 0.4 | 7.1 |
| Cash Conversion Cycle | 23.1 days | 23.6 days | 148.8 days | 46.8 days | 15.8 days |
| Asset Turnover | 1.21x | 1.30x | 1.41x | 0.47x | 7.65x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 567 | N/A | -20 | -199 | -378 |
| Free Cash Flow (OCF − Capex proxy) | 567 | N/A | -20 | -199 | -378 |
| Cash Conversion (OCF / EBITDA) | 69.9% | N/A | -3.2% | -24.6% | -33.9% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →